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Abstract
Background: The extracellular matrix protein SPARC (Secreted Protein, Acidic, Rich in Cysteine) has been linked to
degeneration of the intervertebral discs and chronic low back pain (LBP). In humans, SPARC protein expression is
decreased as a function of age and disc degeneration. In mice, inactivation of the SPARC gene results in the
development of accelerated age-dependent disc degeneration concurrent with age-dependent behavioral signs of
chronic LBP.
DNA methylation is the covalent modification of DNA by addition of methyl moieties to cytosines in DNA. DNA
methylation plays an important role in programming of gene expression, including in the dynamic regulation of
changes in gene expression in response to aging and environmental signals.
We tested the hypothesis that DNA methylation down-regulates SPARC expression in chronic LBP in pre-clinical
models and in patients with chronic LBP.
Results: Our data shows that aging mice develop anatomical and behavioral signs of disc degeneration and back
pain, decreased SPARC expression and increased methylation of the SPARC promoter. In parallel, we show that
human subjects with back pain exhibit signs of disc degeneration and increased methylation of the SPARC
promoter. Methylation of either the human or mouse SPARC promoter silences its activity in transient transfection
assays.
Conclusions: This study provides the first evidence that DNA methylation of a single gene plays a role in chronic
pain in humans and animal models. This has important implications for understanding the mechanisms involved in
chronic pain and for pain therapy.
Keywords: SPARC, back pain, DNA methylation, epigenetics, intervertebral disc, aging, gene expression, disc
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Background
Chronic low back pain (LBP) is a complex continuum of
painful conditions that includes both axial and radicular
pain [1]: Axial LBP is defined as spontaneous or move-
ment-evoked pain or discomfort localized to the spine and
low back region. Non-axial, radiating LBP is pain in one
or both legs. Often referred to as radicular pain or sciatica,
i tu s u a l l yf o l l o w st h ec o u r s eo ft h es c i a t i cn e r v e .C u r r e n t
diagnostic and therapeutic approaches to chronic back
pain are limited by our narrow understanding of the
underlying biological mechanisms. There are many poten-
tial causes of chronic LBP including degenerative disc
disease (DDD). While natural age-related degeneration of
intervertebral discs (IVDs) is common [2,3], chronic LBP
is associated with increased signs of disc degeneration
[4,5]. Like most other conditions, back pain is the product
of genetic [6,7] and environmental [8,9] influences.
SPARC (secreted protein, acidic, rich in cysteine; aka
osteonectin or BM-40) is an evolutionarily conserved col-
lagen-binding protein present in IVDs. SPARC is known
to influence bone remodeling, collagen fibrillogenesis,
and wound repair [10]. Decreased expression of SPARC
has been associated with aging and degeneration in
human IVDs [11]. Furthermore, targeted deletion of the
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the aging mouse and a behavioral phenotype resembling
chronic LBP in humans [12,13]. The genetic evidence
from mice and the clinical observation that SPARC is
down-regulated in humans with disc degeneration sug-
gests that long-term down-regulation of SPARC expres-
sion may play a critical role in chronic LBP. What are the
mechanisms that could lead to lasting down-regulation
of genes such as SPARC?
One mechanism that is now well established for stable,
long-term programming of gene expression is DNA
methylation. The DNA is covalently modified by the
addition of methyl moieties by an enzymatic DNA
methyltransferase reaction that catalyzes the transfer of a
methyl group from the methyl donor S-adenosyl methio-
nine. What distinguishes DNA methylation in vertebrate
g e n o m e si st h ef a c tt h a tn o ta l lC p G sa r em e t h y l a t e di n
any given cell type, generating cell type-specific patterns
of methylation [14], which confer upon a genome its cell
type-specific identity. Active regulatory regions of the
chromatin, which enable gene expression, are associated
with hypomethylated DNA, whereas hypermethylated
DNA is packaged in inactive chromatin resulting in gene
silencing [15,16]. Patterns of DNA methylation are gener-
ated during gestation and until recently were believed to
be restricted to life-long programming of cell type-speci-
fic gene expression [17]. However, recent data suggests
that DNA methylation is dynamic in adult non-dividing
cells and is responsive to environmental signals [18]. It
m i g h tt h e r e f o r ep l a yar o l ei nt h em o d u l a t i o no fg e n e
function in response to a plethora of environmental sig-
nals after birth and throughout life [19].
We tested the hypothesis that DNA methylation occur-
ring later in life or in pathological conditions might play a
role in chronic LBP. The possibility that DNA methylation
might precipitate chronic pain through down-regulation
of expression of critical genes such as SPARC has not
been previously addressed.
Our results are consistent with the hypothesis that
alterations in DNA methylation associate with chronic
LBP and IVD degeneration in mice and in humans with
chronic LBP. This data provides the first line of evidence
that supports the hypothesis that DNA methylation is
involved in chronic pain.
Results
Aging and SPARC-null mice exhibit signs of disc
degeneration and back pain
Disc degeneration is known to increase as a function of
aging in both humans and rats [3,20] and is associated
with an increased risk of chronic LBP [4]. In order to
determine the effect of aging on disc degeneration in
mice, disc height was determined from x-rays of the lum-
bar spine in young (3 month), middle-aged (7 month),
and old (15 month) C57B wild-type (WT) mice. Our data
shows reduction in lumbar disc height as a function of
aging (Figure 1a). A similar decrease in disc height was
observed in young 4-month old SPARC-null mice com-
pared to their age-matched WT controls, such that a
4-month old SPARC-null mouse is roughly equivalent to
a normal 15-month old animal in terms of disc anatomy
(Figure 1f). Thus, both normal aging and the deletion of
the SPARC gene results in disc degeneration in mice,
supporting a role for SPARC in maintaining disc
integrity.
We then tested whether age-dependent disc degenera-
tion in mice is associated with behavioral signs of axial
and radicular pain and motor impairment, and whether
it is impacted by loss of function of SPARC.
Axial pain was assessed using a modified version of the
tail suspension assay in which the spontaneous reaction
to gravity-induced strain along the axis of the spine was
measured [21]. Young animals (3 months) spent signifi-
cantly more time in the immobility posture than did
older animals (Figure 1b). This implies a reluctance to
stretch the body axis, which is suggestive of axial pain. A
similar decrease in immobility was observed in 4-month
old SPARC-null mice compared to their age-matched
WT controls (Figure 1g).
Sensitivity to mechanical and cold stimuli in the hind-
paw were used as behavioral indices of radicular pain.
While 7- and 15-month old WT mice developed hyper-
sensitivity to cold as a function of age (Figure 1c), mechan-
ical paw withdrawal thresholds were not significantly
altered (Figure 1d). Similarly, 4-month old SPARC-null
mice presented with cold but not mechanical hypersensi-
tivity compared to their WT controls (Figure 1h,i).
Physical ability was assessed using the accelerating
rotarod assay, in which the latency to fall from a rotating
treadmill is measured. Aging WT mice showed impaired
performance on this task at 7- and 15-months of age,
suggesting the presence of movement-evoked pain and/
or motor dysfunction (Figure 1e). SPARC-null animals
showed a trend towards impaired motor function com-
pared to WT mice at 4-months of age (Figure 1j).
Together, these data indicate that naive WT mice
develop age-dependent disc degeneration along with
behavioral signs of axial and radicular low back pain
and motor impairment.
Aging mice demonstrate changes in expression and DNA
methylation of SPARC
The aging phenotype in WT mice is remarkably similar to
4-month old SPARC-null mice, suggesting that the
absence of the SPARC gene accelerates the normal aging
process in the IVDs, resulting in low back pain. We there-
fore tested whether aging is accompanied by reduced
SPARC expression. A significant decrease in SPARC
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from 15-month-old mice compared to 3-month-old mice
(Figure 2b). This is consistent with the hypothesis that
age-dependent down-regulation of SPARC might be asso-
ciated with chronic LBP and that mechanisms that stably
down-regulate SPARC expression are involved in precipi-
tating chronic pain.
We therefore addressed the question of what is the
mechanism that down-regulates SPARC during aging.
The SPARC promoter has been shown previously to be
modulated by DNA methylation in cancer. Specifically, it
is hypermethylated and silenced in the majority of inva-
sive cervical cancer cases [22]. Cancer epigenetics has
taught us that tumor suppressor genes that are sup-
pressed in cancer because of genetic mutations are
silenced in many other cases by DNA methylation, lead-
ing to similar phenotypes. Interestingly, genes that are
frequently hypermethylated in cancer are also hyper-
methyled with age [23]. We therefore hypothesized that a
similar mechanism operates in chronic LBP, whereby the
age-dependent decrease in SPARC mRNA expression is
due to increased methylation of the SPARC promoter.
DNA was prepared from mouse lumbar discs and the
state of methylation of the SPARC promoter region was
mapped in 3-, 7-, and 15-month old mice. A pyrosequen-
cing analysis of the methylation state of 6 CpG sites
residing in the SPARC gene promoter region (Figure 2a)
showed increased methylation in IVDs with increasing
age at several sites located in the promoter (Figure 2c).
The DNA demethylating agent 5-azacytidine silences
SPARC gene expression in the mouse IVD in vivo
To test whether DNA methylation is involved in silencing
SPARC gene expression in IVD in vivo, we treated 1-year
old mice with the DNA demethylating agent 5-azacytidine
(5AC) (30 mg/kg, i.v. and 250 fmol i.t.). We observed a
significant > 4-fold increase in SPARC mRNA in the 5AC-
treated mice compared to the vehicle-treated controls
(Figure 2d). A pyrosequencing analysis revealed demethy-
lation of the SPARC promoter in animals treated with
5-AC (Figure 2e). To further test the involvement of
SPARC methylation in chronic pain we determined the
relationship between state of methylation of the SPARC
promoter and cold allodynia as a measure of pain. Our
Figure 1 Disc degeneration and behavioral signs of low back pain in aging and SPARC-null mice. Anatomy: The disc height index
measured in 15-month old mice is smaller than that in 3-month old mice (a). 4-month old SPARC-null mice show smaller average disc height
compared to age-matched WT controls (f). Pain Behavior: Aging mice exhibit signs of axial discomfort (b), cold sensitivity (c), but not mechanical
sensitivity (d) in the hindpaw, in addition to overall motor impairment (e) when compared to 3-month old mice. 4-month old SPARC-null
animals show a behavioral profile similar to older WT mice (g-j). * = p < 0.05, ** = p < 0.01, One-way ANOVA followed by Bonferroni’s test
(aging cohorts), two-tailed student t-test (SPARC-null vs WT). n = 8-15/group. Error bars = S.E.M.
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nificantly correlated with the magnitude of cold allodynia
in vivo (Figure 2e, inset).
The mouse and human SPARC promoters are silenced by
DNA methylation in vitro
Our results with 5AC presented in Figure 2 show that
non-specific demethylation can activate the SPARC gene
in vivo. In order to directly determine whether methyla-
tion of the SPARC gene promoter region silences either
mouse or human SPARC promoters we subcloned the
promoter region into a CpG-deficient luciferase reporter
plasmid pCpGL [24]. The same region was subcloned in
the antisense direction as a negative control. We methy-
lated exclusively the sites that were shown to be methy-
lated in vivo using Sss1 DNA methyltransferase (Figure 3a,
b), and compared luciferase activity after transient trans-
fection into HEK293 cells with the same plasmid that was
mock-methylated. The luciferase expression observed in
the control condition was completely silenced by methyla-
tion of both the mouse (Figure 3c) and human SPARC
promoters (Figure 3d), demonstrating that methylation
silences SPARC promoter activity.
SPARC promoter is hypermethylated in LBP patients with
disc degeneration
Given the potential clinical significance of these find-
ings, we examined whether these results could be trans-
lated to humans. Patients with severe chronic LBP were
recruited from a pool of individuals scheduled for spinal
fusion surgery due to severe disc degeneration. Pain free
controls were recruited from the general population. As
anticipated, the surgical group had higher pain and dis-
ability levels than control subjects (Figure 4a, b). The
degree of degeneration of the lumbar spine was deter-
mined by lumbar MRI and was also significantly
increased in patients vs. controls (Figure 4c). These data
indicate that our patient population had significant
increases in disc degeneration, pain, and disability com-
pared to the general population.
Decreases in SPARC expression with age and degen-
eration have been reported elsewhere [11]. Unfortu-
nately, the quality of the RNA derived from the human
Figure 2 Changes in expression and DNA methylation of
SPARC in aging mice. SPARC mRNA expression (relative to gapdh)
at different time points in life (b). Age-dependent changes in
methylation of CG sites in the SPARC promoter (a) in IVDs as
quantified by pyrosequencing (c). Treatment of 1-year old mice with
the demethylating drug 5AC or vehicle (30 mg/kg, i.v. and 250 fmol
i.t.) resulted in a 4-fold increase in SPARC mRNA expression and (d)
decreased methylation of CG sites in the SPARC promoter as
quantified by pyrosequencing in IVDs. Inset: Increased cold
sensitivity following 5AC injection was significantly correlated with
total SPARC methylation. * = p < 0.05, *** = p < 0.001. One-way
ANOVA followed by Bonferroni’s test (aging cohorts) and two-tailed
student t-test (5AC vs. vehicle treated). Pearson’s correlation (p =
0.03, r
2 = 0.46). n = 3-15/group. Error bars = S.E.M.
Figure 3 DNA methylation silences murine and human SPARC
promoter activity. The mouse (a) and human promoter regions (b)
were cloned into a pCPGL-basic plasmid (the CpG positions are
indicated as balloons). There were no CpGs in the vector. The
plasmids were either methylated or mock methylated in vitro and
then transfected into HEK293 cells in the sense or antisense (1
st
column) configuration for 48 h (c, d). Relative luciferase activity
(percentage) in the extracts is shown as average per group
(triplicate transfection). The decrease in expression in the
methylated (3
rd column) vs. unmethylated (2
nd column) treatment
groups indicates gene silencing. One-way ANOVA followed by
Bonferroni’s test. ** = p < 0.01 Error bars = S.E.M.
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mRNA. However, the stability of DNA allowed us to
perform bisulfite mapping of the promoter region.
Increased methylation of the SPARC promoter (Figure
4d) was observed in surgical samples compared to con-
trols. Five out of the thirteen individual sites examined
had significantly increased methylation in the surgical
samples (Figure 4e). Our data supports the hypothesis
that increased DNA methylation of promoters such as
SPARC gene promoter are associated with pain in
humans.
Discussion
The prevalence of chronic pain in the general popula-
tion is estimated at 15-40%. In addition to being a
major health care problem, chronic pain has serious
economic consequences, costing billions of dollars per
year in lost productivity and medical expenses. Chronic
pain is often resistant to therapeutic intervention, and
individuals suffer for years without relief. New therapeu-
tic strategies are desperately needed. Despite enormous
efforts, significant advances in pain management con-
tinue to be elusive.
While a genetic basis for individual variations in the
development of chronic pain is well established [25],
genetics only accounts for approximately half of the
inter-individual variability in chronic low back pain [26].
One concept that is beginning to receive attention in
pain research is the fact that gene function can be altered
not only by differences in gene sequence but also by dif-
ferences in epigenetic modification. Epigenetic modula-
tion refers to chemical modifications of DNA including
DNA methylation that produce long-term changes in
gene expression. These changes can have long-lasting
biological consequences and could become maladaptive,
leading to chronic diseases such as obesity [27], fatigue
[28] or neurological and mental disorders [19,29].
In humans, decreased expression of SPARC is observed
in painful, degenerating discs [11] and deletion of the
SPARC gene triggers accelerated age-dependent disc
degeneration [12] and chronic pain in mice [13]. We
therefore hypothesized that the SPARC gene may be
silenced by DNA methylation as a function of aging in
degenerating discs.
In the current study we show that disc degeneration is
accompanied by signs of axial and radicular pain and
physical impairment in mice (Figure 1) and with pain
and physical disability in humans (Figure 4). Targeted
inactivation of the SPARC gene results in early onset of
both disc degeneration and behavioral indices of LBP in
mice [12,13]. Having established that deletion of SPARC
increases chronic pain and disc generation, we deter-
mined whether this gene is commonly silenced by DNA
methylation during normal aging. Increased disc degen-
eration and chronic pain are associated with age in
rodents and humans.
There are multiple mechanisms by which IVD degenera-
tion can result in chronic axial and/or radicular LBP. In
the periphery, spinal instability due to disc degeneration
could result in irritation of other structures such as the
facet joints, muscles and ligaments. Increased innervation
of degenerating discs by sensory neurons [30] is also
thought to contribute to discogenic pain [31] and contact
with the contents of the disc results in increased neuronal
excitability and sensitization [32,33]. In addition, disc
degeneration may result in radicular pain following nerve
compression due to disc bulging or herniation [34,35].
Within the central nervous system, ongoing nociceptive
input from peripheral structures may result in sensitiza-
tion within the spinal cord or supraspinal structures,
resulting in an exaggerated response to subsequent per-
ipherally applied stimuli (for reviews see [36,37]).
Furthermore, chronic LBP results in changes in brain
structure and function [38,39]. Interestingly, therapeutic
interventions that target the spinal column such as facet
Figure 4 SPARC mRNA expression and DNA methylation in IVDs
from chronic LBP patients with disc degeneration. Pain intensity
measured with the numeric rating scale (a) and physical disability as
determined by the Oswestry Disability Index (b) were increased in
surgical patients, as was lumbar disc degeneration based on scoring
of MRI images (c). The state of methylation of CG sites in the human
SPARC promoter (d) in L4-L5 IVDs was increased as quantified by
pyrosequencing (e) * = p < 0.05, ** = p < 0.01, *** = p < 0.001. Two-
tailed student t-test. n = 5-8/group. Error bars = S.E.M.
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changes in the brain, suggesting that ongoing input from
the periphery actively maintains pain-related CNS plasti-
city [39]. While the current study is focused on the epige-
netic modulation of the degeneration of a peripheral
structure, studies examining the role of epigenetics in
pain-related CNS plasticity are needed.
We provide several lines of evidence that support the
hypothesis that DNA methylation occurs during aging and
that it results in silencing of SPARC. First, the state of
methylation of several CG sites in the promoter is
increased with aging. Second, DNA methylation inhibitors
resulted in demethylation of the SPARC promoter and
increased expression of SPARC in vivo. Third, methylation
of CG sites in the promoter lead to silencing of promoter
activity. The combination of the genetic evidence for the
role of SPARC in chronic pain and the DNA methylation
analysis provide strong support for the idea that DNA
methylation occurs during aging and that it is involved in
disc degeneration and chronic LBP. Although it was not
possible to provide direct evidence of SPARC mRNA
expression in clinical samples, we tested whether the clini-
cal situation is consistent with our hypothesis. We show
that discs removed from patients that suffered from
chronic LBP also exhibited increased methylation of
t h eS P A R Cg e n e( F i g u r e4 ) .The human promoter, like
the mouse promoter, is silenced by DNA methylation
(Figure 3).
Unlike the static genome, the epigenome is in dynamic
equilibrium throughout our lifespan and DNA methyla-
tion is a bidirectional process that can be altered by phar-
macological agents [40]. Changes in methylation appear
to be a common feature in aging cells and tissues. Epige-
netics also plays a key role in the development of diseases
associated with aging including cancer [41,42], athero-
sclerosis, and neurodegenerative and autoimmune disor-
ders [43]. Interestingly, age itself is a risk factor for
chronic pain in humans [44]. Using the candidate gene
approach, we demonstrate that aging is one physiological
process that could lead to hypermethylation and silencing
of SPARC. It is likely that aging results in silencing of
additional genes that are involved in chronic pain either
in the periphery or the central nervous system. Moreover,
it stands to reason that other transient environmental
exposures such as tissue injury could result in DNA
methylation of many other genes, which could serve as a
long-term memory of such exposures in the genome,
resulting in chronic pain.
Conclusions
Our study provides the first line of evidence that DNA
methylation is involved in chronic pain. Specifically, we
present evidence from both mouse and human studies
supporting the hypothesis that DNA methylation of the
SPARC promoter is increased with age and intervertebral
disc degeneration, resulting in the silencing of a gene
that is protective against accelerated disc degeneration.
The SPARC gene is likely to be just one example of many
pain-relevant genes that are similarly regulated by DNA
methylation in both peripheral tissues and in the central
nervous system.
Epigenetic modifications are at the interface between
environment and genetics, creating a mechanism by
which life experience can lead to long-lasting changes in
gene expression. If DNA methylation is implicated in
chronic pain, it will provide not only new understanding
of the underlying mechanisms involved in generation
and maintenance of chronic pain, but also new thera-
peutic possibilities.
Methods
Animals
All procedures were approved by the Animal Care Com-
mittee at McGill University, and conformed to ethical
guidelines of the Canadian Council on Animal Care.
Female C57BL/6 mice were used in this study. The
SPARC-null mouse [45] was backcrossed onto a standard
C57BL/6 background for > 12 generations [46]. All animals
were bred and aged in-house and experienced identical
environments. Experiments were performed blind to geno-
type and age.
Mouse Behavioral Assays
Axial Pain: Tail Suspension Assay
Mice were suspended underneath a platform by the tail
with adhesive tape attached 0.5-1.0 cm from the base of
the tail and videotaped for 3 minutes. The duration of
time spent in a) immobility (not moving but stretched
out), b) rearing (trying to reach the underside of the plat-
form), c) full extension (actively reaching for the floor),
and d) self-supported (holding either the base of its tail or
the tape) were determined [21].
Radicular Pain: Sensitivity to Cold Stimuli
Spontaneous nociceptive behaviors (flinching, licking or
biting) were measured for 1 minute after a drop of acet-
one (~25 μl) was applied to the hindpaw as previously
described [13].
Radicular Pain: Sensitivity to Mechanical Stimuli
A series of calibrated monofilaments (von Frey fila-
ments) were applied with increasing force to the plantar
surface of the hindpaw until the animal responded by
withdrawing. A decrease in threshold suggests the devel-
opment of mechanical hypersenstivity. Results are
expressed as the threshold (in grams) to withdraw 50%
of the time as previously described [13].
Rotarod Assay
We used the accelerating rotarod assay to monitor ani-
mals for decreased motor function [47]. The latency to
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the test was 5 minutes.
Radiographic assessment of IVD degeneration in Mice
Aging WT mice were anaesthetized and x-rays were
obtained using a Faxitron 3000. For SPARC-null and WT
control mice, radiography was performed ex vivo.D i s c
height was calculated for all lumbar IVDs (Figure 5). The
observer was blind to age and genotype.
Human Subjects
Procedures involving human subjects were approved, as
applicable, by the following Institutional Review Boards:
McGill University Faculty of Medicine, McGill University
Health Centre, The University of Minnesota and Allina
Health Care (Minneapolis, MN).
Three groups of human subjects were used in this
study. Additional information on human subjects can be
found in Additional File 1.
Experimental Subjects
The experimental group was recruited from a pool of
patients scheduled for spinal fusion to treat severe cLBP
associated with lumbar disc degeneration (mean age =
45.6 ± 2.8, n = 10, 3 males, 5 females, 2 unknown; see
Additional File 1). Following surgical removal, discs were
rinsed briefly in PBS, sectioned into quadrants, flash fro-
zen in liquid nitrogen and stored at -80C.
Healthy Pain-Free Controls
A healthy control group consisting of individuals free of
back pain was used as a comparator for the pain and dis-
ability assessments and disc degeneration scores in the
surgical samples. (mean age = 41.2 ± 2.3, n = 23, 14 males
and 9 females). No tissue was available from these
subjects.
Non-Degenerated Control Discs
Non-degenerated control IVDs were acquired with the
cooperation of Transplant Quebec from tissue donors.
Lumbar spinal columns were extracted intact and placed
on ice for transport. While age, sex and cause of death is
recorded, no information is available regarding the pre-
sence of back pain or physical disability before death.
X-rays were obtained of lumbar spines prior to IVD dis-
section and discs with obvious signs of degeneration
(reduced height, calcification, bony spurs) were excluded
from the study. Following x-ray of the entire column, the
IVDs were dissected and stored at -80 until use. (mean
age = 58.2 ± 4.4, n = 5 males, see Additional File 1).
Pain and disability assessment in human subjects
Pain was assessed using the numeric rating scale in
which subjects rate pain intensity on a scale of 0-100,
where 100 is the worst pain imaginable. Pain-related dis-
ability was determined using the Oswestry Disability
Index (ODI) questionnaire [48].
Radiographic assessment of IVD degeneration in human
subjects
Lumbar MRIs were obtained for all surgical and healthy,
pain-free control subjects. Each lumbar disc was scored
using the 5-point Pfirrmann scale [49] by a radiologist
blind to diagnosis.
Bisulfite mapping and expression analyses
DNA was treated with sodium bisulfite and primers were
designed for converted products of both mouse [GenBank:
AL596207.10] and human [GenBank: AC011374.6] SPARC
promoters. PCR products were sequenced using the Bio-
tage Pyrosequencer according to the manufacturer’sp r o t o -
col (See Additional File 2 for primer sequences) [50].
Expression of SPARC [GenBank: AK003162.1] was quanti-
fied using quantitative RT-PCR on the Lightcycler 480
using GAPDH [GenBank: AK002273.1] for normalization.
RNA extraction was carried out using Trizol (Invitro-
gen) and followed by Dnase I treatment and cDNA con-
version using random hexamers (Roche Molecular
Biochemicals) according to manufacturer’s instructions.
Expression of SPARC was then quantified using quantita-
tive RT-PCR on the Lightcycler 480 using GAPDH for
normalization. SPARC primers for human and mouse are
listed in Additional File 2.
Bisulfite PCRs were amplified using two rounds of PCR
using outer and nested primers (see Additional File 2).
Cycling conditions involved an initial step of 5 minutes at
95°C followed by 35 cycles of [95°C for 1 minute, Tm for
2.5 minutes, 72°C 1 minute] Followed by 5 minutes of
72°C. Luciferase construct PCRs were made with primers
(See Additional File 2) using the same cycling conditions
only with one round of PCR. Quantitative PCR was ampli-
fied with a pre-incubation at 95°C for 10 minutes followed
by 45 cycles of [95°C for 10 seconds, 60°C for 10 seconds,
72°C for 10 sec] followed by 10 minutes of 72°C.
Figure 5 Calculation of Disc Height Index from Mouse Lumbar
Spinal X-ray. Lateral x-ray images of the intact lumbar spine were
taken at 4× using a Faxitron
® MX-20 (Faxitron X-Ray LLC,
Lincolnshire, IL). Disc Height Index (DHI) was determined according
to the following equation: Disc Height Index (DHI) = 2 × (DH1 +
DH2 + DH3)/(A1 + A2 + A3 + B1 + B2 + B3) where A and B
represent the length of the vertebral bone immediately rostral and
caudal to the IVD, respectively; and DH represents the disc height
between adjacent vertebrae.
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Human and mouse SPARC promoters were subcloned
into the CpG-less pCpGL luciferase reporter plasmid
[24] in both 5’ to 3’ (sense) or 3’ to 5’ (antisense) orien-
tation, respectively.
The constructs were methylated in vitro with SssI
CpG DNA methyltransferases (New England Biolabs,
Inc.) as recommended by the manufacturers.
Transfections were performed using calcium phosphate
precipitation as described previously) [51]. Cells were har-
vested 48 h after transfection and luciferase activity was
assayed using the Luciferase Assay System (Promega).
Statistical analysis
All data are plotted as mean ± SEM. The student t-test
(2-tailed, unpaired) was used in data comparing two
groups. One-way ANOVA followed by Bonferroni’s test
was used when comparing 3 groups. For the luciferase
assay, data is shown in the percentile form. All data was
analyzed and graphed using Prism 4.0 (GraphPad Soft-
ware, Inc., La Jolla, CA).
Additional material
Additional file 1: Subject information from cadaveric and surgical
human IVD samples. Gender, Age and Cause of Death (if applicable) is
indicated for all human intervertebral disc samples used in this study.
Additional file 2: Primer Sequences. Provides the sequences and Tm (°
C) for the Bisulfite PCR Primers, Expression Primers, Luciferase Construct
Primers and Pyrosequencing Primers used in this study.
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